Recursion Pharmaceuticals Inc - Class A RXRX

NAS: RXRX | ISIN: DE0007201980 17/05/2024

9,420 USD (-0,95%)

(-0,95%) 17/05/2024

Grafiek Recursion Pharmaceuticals Inc - Class A

Grafiek Recursion Pharmaceuticals Inc - Class A

1 dag1d -0,95%
1 week1w -0,63%
1 maand1m 23,95%
3 maanden3m -25,18%
6 maanden6m 37,32%
1 jaar1j 16,01%
5 jaar5j -69,90%

Recursion Pharmaceuticals Inc - Class A in het nieuws

Toon enkel gratis nieuws

1 februari 2023 · Recursion to Participate in Upcoming Investor Conference · Persbericht

26 januari 2023 · Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day · Persbericht

20 december 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

8 november 2022 · Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results · Persbericht

2 november 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

25 oktober 2022 · Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB · Persbericht

13 september 2022 · Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 · Persbericht

1 september 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

18 augustus 2022 · Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum · Persbericht

9 augustus 2022 · Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results · Persbericht

Profiel Recursion Pharmaceuticals Inc - Class A

Werknemers: 515

Aandelen Recursion Pharmaceuticals Inc - Class A

Beurswaarde: 2,17 miljard USD

Effecten: 230,27 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 2,80

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe